COPE Advertising options


Cell Sciences Inc http://www.promokine.info/products/cytokines-growth-factors/cytokines-growth-factors-soluble-receptors/animal-free-endotoxin-free-cytokines-growth-factors/ PBL Assay Science

COPE Homepage Bottom of page Previous entry:
basophilopoietin
Next entry:
BASP1
Random entry:
membranous pneumocytes
Search COPE:

Please donate

If you find COPE helpful,
please show your appreciation
by donating what you can afford.

basophils

Basophils are a type of bone marrow-derived granulocytes (basophilic granulocytes) that comprise less than 1 % of the circulating leukocytes. The nuclei aqre less heterochromatic than those of other granulocytes and stains with basophilic dyes (see also: basophil cells). These cells contain large irregularly shaped specific granules that often obscure the multilobed nucleus. These specific granules are similar to granules of mast cells in that they contain histamine and a heparin-like compound.

Tissue basophils resemble mast cells although their biochemical and morphological features may differ, depending upon the kind of tissue they reside in. They are differentiated from blood basophils by the fact that they are often twice the size of blood basophils, and have irregular and frequently elongated spindle shapes with cytoplasmic extensions.

Basophils arise from CD34(+) progenitor cells found in cord blood, peripheral blood, and the bone marrow, in particular cells that are CD34(+), express the receptors for IL3 and IL5 and are considered eosinophil basophil progenitors (Boyce et al, 1995). Basophils complete their differentiation within the bone marrow, whereas precursors of mast cells leave the bone marrow and differentiate into mast cells after having invaded connective or mucosal tissues.

Basophils have long been regarded as circulating mast cells and share a number of characteristics with eosinophils but blood basophils and mast cells are distinct hematopoietic cells (Falcone et al, 2000). Mature basophils can be distinguished phenotypically from mast cells. Basophils express the alpha chain of the IL3 receptor, which is not expressed by mast cells. Mast cells erxpress the kit receptor (SCF receptor, which is not expressed, or only weakly, on mature basophils).

Basophils play an important role in inflammatory reactions and as multifunctional effector cells in IgE-mediated reactions and are recruited rapidly to various organs sites during allergic late phase reactions (Charlesworth et al, 1989; Liu et al, 1991; Bascom et al, 1988). They have been identified as antigen-capturing cells that may function as important regulators of humoral immune responses.

Basophils release a plethora of potent inflammatory mediators from their cytoplasmic granules upon appropriate stimulation. This process is called degranulation. Degranulation can be caused by a wide range of signals, including high temperature, mechanical trauma, ionizing, toxins, venoms, proteases, tissue proteases, cationic proteins derived from eosinophils and neutrophils, IgE-dependent mechanisms, or IgE-independent immune mechanisms, for example through complement factors. Low molecular weight mediators include histamine, serotonin, prostaglandins, leukotrienes. It is the contents of basophil granules released in response to the presence of allergens that cause increased vascular permeability, smooth muscle spasm, vasodilation, and the clinical symptoms of an allergic reaction.

Many different factors are involved in the regulation of functional activities of basophils and influence their adhesion properties, migration, localization, proliferation, and phenotype.

For related information of interest see also: Cell types, Cell lines in Cytokine Research, Cell culture. For other entries pertaining to hematopoiesis see also the Hematology Dictionary section of this encyclopedia.

Basophils have been shown to possess the capacity to express the proteins listed below. Please note the following general observations, which practically apply to all cell types: expression may be influenced by tissue localization, may occur only in discrete subpopulations of cells, may vary between established cell lines, primary cells, embryonic cells, mature cells, fully differentiated cells, activated cells, non-activated cells or growth conditions (confluent vs. sparse cultures), may be influenced by various disease states (including cancer environment), and may differ between species.
Note also: expression profile information lists entities only for which there is an entry in COPE or one of its subdictionaries.

The meaning of ¥ and ¥¥ is as follows: ¥ factor/protein is expressed; ¥¥ receptor (or, in some instances, binding sites) for this factor/protein is expressed. For further explanations concerning format, "hidden" information, and/or ambiguities see my remarks in the entry cell types.


¥ Annexin-1 (Annexin A1, ANX1, ANXA1, lipocortin-1, LPC1, LCT1, LC1, Lipo1, macrocortin, renocortin, lipomodulin, GIF, glycosylation inhibiting factor, CB9, chromobindin-9, calpactin-2) (Morand et al, 1995)

¥ basigin (BSG, CD147, EMMPRIN, extracellular matrix metalloproteinase inducer, 5A11, CE-9, Collagenase stimulatory factor, gp42, HT7, M6, neurothelin, Oka blood group antigen, OX47) (Wimazal et al, 1999)
¥ Basogranulin (BB1) (McEuen et al, 2001)
¥ BCLxL (BCL2-like-1, BCL2L1) (Didichenko et al, 2008)
¥ BIRC3 (baculoviral IAP repeat-containing protein-3, API2, Apoptosis inhibitor 2, CA2_1, MIHC, mammalian IAP homolog C, HIAP1, Human inhibitor of apoptosis protein-1, cIAP2, cellular IAP2, TNFR2-TRAF signaling complex protein 1, RNF49, RING finger protein 49) (Didichenko et al, 2008)
¥ Bsp-1 (Valent et al, 1990; Bodger et al, 1987)

¥ C3a receptors (FŸreder et al, 2001)
¥ CCL2 (CC chemokine ligand 2, chemokine (C-C motif) ligand 2, GDCF, Glioma-derived monocyte chemotactic factor-2, GDCF-2, HC11, JE, LDCF, MCAF, MCP, monocyte chemoattractant protein, MCP-1, monocyte chemoattractant protein-1, SMC-CF, smooth muscle cell chemotactic factor, TDCF, tumor-derived chemotactic factors, TSG-8, tumor necrosis factor-stimulated gene sequence-8, SCYA2) (Kondo et al, 2008)
¥¥ CCL2 (CC chemokine ligand 2, chemokine (C-C motif) ligand 2, GDCF, Glioma-derived monocyte chemotactic factor-2, GDCF-2, HC11, JE, LDCF, MCAF, MCP, monocyte chemoattractant protein, MCP-1, monocyte chemoattractant protein-1, SMC-CF, smooth muscle cell chemotactic factor, TDCF, tumor-derived chemotactic factors, TSG-8, tumor necrosis factor-stimulated gene sequence-8, SCYA2) receptors (Alam et al, 1992; Kuna et al, 1993)
¥ CCL3 (CC chemokine ligand 3, chemokine (C-C motif) ligand 3, MIP-1-alpha, macrophage inflammatory protein-1-alpha, 464.1, GOS-19-1, L2G25B, LD78, LD78-alpha, SCI, stem cell inhibition factor, stem cell inhibitor, TY5, SCYA3, SCYA3L1) (Ying et al, 2001; Li et al, 1996; Kondo et al, 2008)
¥¥ CCL3 (CC chemokine ligand 3, chemokine (C-C motif) ligand 3, MIP-1-alpha, macrophage inflammatory protein-1-alpha, 464.1, GOS-19-1, L2G25B, LD78, LD78-alpha, SCI, stem cell inhibition factor, stem cell inhibitor, TY5, SCYA3, SCYA3L1) receptors (Kuna et al, 1993; Li et al, 1996; Heinemann et al, 2005)
¥ CCL4 (CC chemokine ligand 4, chemokine (C-C motif) ligand 4, SCYA4, ACT-2, Immune activation gene-2, 744.1, G26, H400, HC21, Cytokine 21, human, LAG-1, lymphocyte activation gene-1, MIP-1-beta, macrophage inflammatory protein-1-beta, SIS-gamma) (Kondo et al, 2008)
¥¥ CCL4 (CC chemokine ligand 4, chemokine (C-C motif) ligand 4, SCYA4, ACT-2, Immune activation gene-2, 744.1, G26, H400, HC21, Cytokine 21, human, LAG-1, lymphocyte activation gene-1, MIP-1-beta, macrophage inflammatory protein-1-beta, SIS-gamma) receptors (Kuna et al, 1993)
¥ CCL5 (CC chemokine ligand 5, chemokine (C-C motif) ligand 5, RANTES, EoCP-1, Eosinophil chemotactic polypeptide-1, SIS-delta, TCP228, T-cell-specific protein p228, SCYA5) (Kondo et al, 2008)
¥¥ CCL5 (CC chemokine ligand 5, chemokine (C-C motif) ligand 5, RANTES, EoCP-1, Eosinophil chemotactic polypeptide-1, SIS-delta, TCP228, T-cell-specific protein p228, SCYA5) receptors (Alam et al, 1992; Kuna et al, 1993)
¥¥ CCL8 (CC chemokine ligand 8, chemokine (C-C motif) ligand 8, SCYA8, MCP-2, monocyte monocyte chemoattractant protein-2, HC14, Cytokine 14, human) receptors (Heinemann et al, 2005)
¥ CCL11 (CC chemokine ligand 11, chemokine (C-C motif) ligand 11, SCYA11, Eotaxin, Eotaxin-1) (Gilmartin et al, 2008)
¥¥ CCL11 (CC chemokine ligand 11, chemokine (C-C motif) ligand 11, SCYA11, Eotaxin, Eotaxin-1) receptors (Menzies-Gow et al, 2002; Heinemann et al, 2005)
¥ CCL15 (CC chemokine ligand 15, chemokine (C-C motif) ligand 15, HCC2, hemofiltrate CC-Chemokine-2, NCC3, new CC chemokine-3, MIP-5, macrophage inflammatory protein-5, Lkn-1, leukotactin-1, MIP-1-delta, macrophage inflammatory protein-1-delta, HMRP-2B, human MIP-related protein 2B, SCYL3, SCYA15) (Gilmartin et al, 2008)
¥ CCL22 (CC chemokine ligand 22, chemokine (C-C motif) ligand 22, ABCD-1, DC/B-Ck, dendritic cell/B-cell derived chemokine, MDC, Human macrophage-derived chemokine STCP-1, stimulated T-cell chemotactic protein, SCYA22) (Watanabe et al, 2008)
¥¥ CCL24 (CC chemokine ligand 24, chemokine (C-C motif) ligand 24, MPIF-2, Myeloid progenitor inhibitory factor-2, Ck-beta-6, Chemokine-beta-6, eotaxin-2, SCYA24) receptors (Menzies-Gow et al, 2002)
¥ CCR1 (CC-Chemokine receptor 1, RANTES receptor, MIP-1-alpha receptor, LD78 receptor, CC-CKR1, HM145, YT4, CD191, CMKBR1, chemokine-beta receptor 1) (Iikura et al, 2001; Ying et al, 2001; Florian et al, 2006)
¥ CCR2 (CC-Chemokine receptor 2, CC-CKR2A, CCR2A, CC-CKR2B, CCR2B, MCP-1 receptor A, MCP-1 receptor B, CMKBR2, chemokine-beta receptor 2, CD192) (Iikura et al, 2001; Heinemann et al, 2000; Ochensberger et al, 1999; Garcia-Zepeda et al, 1996; Florian et al, 2006)
¥ CCR3 (CC-Chemokine receptor 3, CC-CKR3, Eotaxin receptor, CMKBR3, chemokine-beta receptor 3, MIP-1-alpha RL2, MIP-1-alpha receptor-like-2, CD193) (Iikura et al, 2001; Heinemann et al, 2000; Ying et al, 1999; Ochensberger et al, 1999; Garcia-Zepeda et al, 1996; Uguccioni et al, 1997; Ying et al, 1999; Suzukawa M et al, 2008)
¥ CCR4 (CC-Chemokine receptor 4, CC-CKR4, CKR4, CMKBR4, chemokine-beta receptor 4, K5-5, CD194) (Power et al, 1995)
¥ CCR5 (CC-Chemokine receptor 5, CC-CKR5, CMKBR5, ChemR13, CD195) (Iikura et al, 2001)
¥ CCR7 (CC-Chemokine receptor 7, EBI-1, EBV induced gene-1, blr-2, CMKBR7, Burkitt lymphoma receptor-2, CD197) (Florian et al, 2006)
¥ CD4 (T4, Leu3, OKT4, L3T4, Ly4, W3/25, OX38, OX35) (Stain et al, 1987)
¥ CD9 (602-29 antigen, ALB6 antigen, BA2, BTCC-1, DRAP-27, Diphtheria toxin receptor associated protein 27 kDa, GIG2, MIC3, MRP-1, Motility-related protein-1, NCA, neural cell surface antigen, p24, SH-9, TSPAN29, tetraspanin 29) (Stain et al, 1987; Han et al, 2008)
¥ CD11a (ITGAL, integrin-alpha-L, LFA-1, Ly15, Ly21, LFA-1, lymphocyte function-associated antigen-1, LFA-1-alpha, lymphocyte function-associated antigen-1-alpha, neutrophil adherence receptor alpha-M subunit, OND(a), OND) (FŸreder et al, 1994; Sperr et al, 1992; Toba et al, 1999; Bodger and Newton, 1987)
¥ CD11b (CR3, CR3a, complement receptor-3, C3bi receptor, ITGAM, integrin-alpha-M, HNA4a, human neutrophil antigen 4a, MART, MART(a), Mo1, Ly40, Mac-1, OKM1, OX42, VIM12) (FŸreder et al, 1994, 1995, 2001; Hartnell et al, 2004; Sperr et al, 1992; Monneret et al, 2005; Yoshimura-Uchiyama et al, 2003; Heinemann et al, 2005; Kepley et al, 1998; Suzukawa M et al, 2008)
¥ CD11c (CR4, complement receptor-4, iC3b receptor, ITGAX, integrin-alpha-X, Leu M5, myeloid membrane antigen, OX42, p150,95) (FŸreder et al, 1994, 1995, 2001; Sperr et al, 1992; Siegmund et al, 2000; Toba et al, 1999)
¥ CD13 (alanyl aminopeptidase, AAP, ANPEP, alpha-aminoacyl-peptide hydrolase (microsomal), aminopeptidase N, PEPN, APN, APM, aminopeptidase M, EC3.4.11.2, LAP1, microsomal aminopeptidase, MY7, MCS-2, gp150) (FŸreder et al, 1994; Griffin et al, 1981; Toba et al, 1999; Stain et al, 1987; Bodger and Newton, 1987; Han et al, 2008; Seldin et al, 1986; Bodger and Newton, 1987; Hennersdorf et al, 2005; Kneidinger et al, 2008)
¥ CD14 (endotoxin receptor, Leu M3, LPS-R, Mo2, MY4, myeloid cell-specific leucine-rich glycoprotein, hdl, heedless) (Toba et al, 1999)
¥ CD15 (3-FAL, 3-Fucosyl-N-Acetyllactosamine, 3-FL, 3-Fucosyl-lactosamine, 80H.5, AGF 4.48, C3D-1, DAKO-M1, ELFT, ELAM-1 ligand fucosyltransferase, FAL, Fucosyl-N-Acetyllactosamine, 3-alpha-fucosyl-N-acetyl-lactosamine, FCT3A, alpha-3-fucosyltransferase, FUC-T-IV, fucosyltransferase 4, FUT-4, fucosyltransferase 4, LeuM1, LeX, Lewis X, X-hapten, hapten X, X-determinant, LNF-3, lacto-N-fucopentaose 3, LNFP-3, Lacto-N-Fucopentose 3 ceramide, MMA, My-1, myeloid-associated surface antigen, PMN7, polymorphonuclear leukocyte antigen 7, SSEA-1, stage-specific embryonic antigen-1) (Toba et al, 1999; Stain et al, 1987)
¥ CD15s (CD15, 3-FAL, 3-Fucosyl-N-Acetyllactosamine, 3-FL, 3-Fucosyl-lactosamine, 80H.5, AGF 4.48, C3D-1, DAKO-M1, ELFT, ELAM-1 ligand fucosyltransferase, FAL, Fucosyl-N-Acetyllactosamine, 3-alpha-fucosyl-N-acetyl-lactosamine, FCT3A, alpha-3-fucosyltransferase, FUC-T-IV, fucosyltransferase 4, FUT-4, fucosyltransferase 4, LeuM1, LeX, Lewis X, X-hapten, hapten X, X-determinant, LNF-3, lacto-N-fucopentaose 3, LNFP-3, Lacto-N-Fucopentose 3 ceramide, MMA, My-1, myeloid-associated surface antigen, PMN7, polymorphonuclear leukocyte antigen 7, SSEA-1, stage-specific embryonic antigen-1) (Wimazal et al, 1999)
¥ CD16b (Fc-gamma R3b, Fc-gamma R3-beta, Fc-gamma receptor III-1, HNA1; HNA1a, human neutrophil antigen 1a, NA1, neutrophil alloantigen 1, HNA1b, human neutrophil antigen 1b, NA2, neutrophil alloantigen 2, NC1, HNA1c, human neutrophil antigen 1c, SH antigen) (Meknache et al, 2009)
¥ CD18 (ITGB2, integrin-beta-2, 2E6, AURA46, augmented in rheumatoid arthritis 46) (Bochner et al, 1996; FŸreder et al, 1994, 1995; Kepley et al, 1998; Sperr et al, 1992)
¥ CD20L (CD20-like, MS4A3, Membrane-spanning 4-domains subfamily A member 3, HTm4, Hematopoietic-specific transmembrane protein 4) (Kutok et al, 2011)
¥ CD21 (B2, C3d receptor, CR2, complement receptor-2, C3dR, complement 3d receptor, C3d receptor, EBV receptor, Epstein-Barr virus receptor) (Bacon et al, 1993)
¥ CD22 (CD22a, CD22-alpha, CD22b, CD22-beta, CD22c, CD22.1, CD22.2, HD6 antigen, HD39 antigen, BLCAM, B-lymphocyte cell adhesion molecule, Leu14, Lyb8, Lyb8.2, Lyb8a, SIGLEC-2, sialic acid binding immunoglobulin-like lectin 2) (Toba et al, 2002; Han et al, 1999; Han et al, 2008)
¥ CD23 (CD23a, CD23b, FCER2, Fc-epsilon R2, Leu20, B6, Blast-2, 18.6 antigen, Ly42, CLEC4J, C-type lectin domain family 4 member J, EBVCS, EBV cell surface antigen, EBVCS1, EBVCS2, EBVCS3, EBVCS4, EBVCS5, MHM6) (Stain et al, 1987)
¥ CD26 (1F7, 2B9, 5F8, ACT-3, ADABP, ADA binding protein, ADCP2, adenosine deaminase complexing protein 2, BT5/9, DPCR1, DPP4, dipeptidyl peptidase 4, HAM.4, intestinal dipeptidyl peptidase, EC3.4.14.5, OX61, TA1, TA5/9, THAM, thymocyte-activating molecule, TP103, WC10 antigen, FAP-beta, Fibroblast activation protein-beta) (FŸreder et al, 1994; Valent et al, 1990)
¥ CD29 (FNRB, fibronectin receptor beta chain, ITGB1, integrin-beta-1, platelet protein GPIIa, VLA-beta, very late activation antigen-beta, VLA-beta-1, VLA-4 beta subunit) (Bochner et al, 1996; Kepley et al, 1998; Sperr et al, 1992; Warner et al, 1995)
¥ CD31 (EndoCAM, endothelial cellular adhesion molecule, ER-MP12, PECAM-1, platelet-endothelial cell adhesion molecule 1) (FŸreder et al, 1994; Valent et al, 1990)
¥ CD32 (hFcRII, Fc-gamma R2, FCG2, FCGR2, CD32a, CD32b, FCGR2A, Fc-gamma R2a, FCGR2B, Fc-gamma R2b, IGFR2, immunoglobulin G Fc receptor 2) (Siegmund et al, 2000; Takahashi et al, 1993)
¥ CD33 (CD33M, CD33m, MY9, SIGLEC-3, sialic acid binding immunoglobulin-like lectin 3) (Siegmund et al, 2000; Toba et al, 1999; Stain et al, 1987; Han et al, 2008)
¥ CD35 (C3 binding protein, C3b receptor, C3bR, C3b/C4b receptor, C4b receptor, complement 3b/4b receptor, CR1, complement receptor-1, Knops blood group antigen, Kn(a), Kn(b), McCoy blood group antigen, McC, Swain-Langley blood group antigen, Sl, Yk(a), York blood group antigen) (FŸreder et al, 1994, 1995, 2001; Siegmund et al, 2000)
¥ CD36 (collagen type 1 receptor, FAT, fatty acid translocase, glycoprotein 3b, GP4, platelet glycoprotein 4, GPIIIb, Naka blood group antigen, OKM5, PAS-4 protein, periodic acid/Schiff-positive protein 4, PASIV, periodic acid/Schiff-positive band 4, platelet collagen receptor, thrombospondin receptor, UA009, obl, oblivious) (Han et al, 2008)
¥ CD38 (ADP-ribosyl cyclase, ADP-ribosyl cyclase-1, cyclic ADP-ribose hydrolase, ecto-NAD+ glycohydrolase, Ecto-nicotinamide adenine dinucleotide glycohydrolase, EC3.2.2.5, Leu17, OKT10, T10) (FŸreder et al, 1994; Toba et al, 1999; Han et al, 2008)
¥ CD40 (Bp50, TNFRSF5, TNF receptor superfamily member 5) (Agis et al, 1996)
¥ CD40 ligand (CD40L, CD40LG, TRAP, TNF-related activation protein, CD154, 5c8, gp39, Ly62, T-BAM, IMD3, TNFSF5, TNF ligand superfamily member 5) (Yanagihara et al, 1998; Gauchat et al, 1993; Siegmund et al, 2000)
¥ CD43 (3E8 antigen, GALGP, galactoglycoprotein, gpL115, L60, Leu22, Lp-3, LSN, leukosialin, Ly48, MT1, OX75, S7 antigen, SPN, sialophorin, W3/13) (FŸreder et al, 1994; Valent et al, 1990)
¥ CD44 (CDw44, CD44H, CD44A, CD44s, CD44st, CD44std, AnWj blood group antigen, ECMR-3, extracellular matrix receptor-3, class 3 ECMR, gp85, HCAM, homing-associated cell adhesion molecule, Hermes-1, Hermes antigen, HUTCH-1, Indian blood group antigen, In blood group antigen, Ly24, MC56, MDU2, MDU3, MIC4, MUC 2-63, OX49, PGP1, PGP1.1, phagocytic glycoprotein-1, GM35 antigen) (FŸreder et al, 1994; Yoshimura et al, 2002; Valent et al, 1990)
¥ CD45 (B220, HuLy-m4, LCA, leukocyte common antigen, Ly5, OX1, OX22, OX30, PTPRC, protein tyrosine phosphatase receptor type C, EC3.1.3.4, T200) (FŸreder et al, 1994; Gane et al, 1993; Bodger and Newton, 1987; Han et al, 2008)
¥ CD46 (gp45-70, HuLy-m5, MCP, membrane cofactor protein, measles virus receptor, MIC10, TLX, TRA-2-10, trophoblast-leukocyte common antigen, trophoblast-lymphocyte cross-reactive antigen) (FŸreder et al, 1994, 1995, 2001)
¥ CD47 (1D8, B6H12, BRIC 126, IAP, integrin-associated protein, integrin-associated signal transducer, MER6, OA3, ovarian carcinoma antigen 3, OVTL3) (FŸreder et al, 1994)
¥ CD49b (Br alloantigen, DX5, ECMR-2, extracellular matrix receptor-2, GPIa, HPA-5, human platelet antigen-5, ITGA2, integrin-alpha-2, platelet glycoprotein Ia/IIa, VLA-2, very late activation antigen 2, VLAA2, VLA2 receptor alpha 2 subunit, VLA-alpha 2, very late activation antigen alpha-2, Zav alloantigen) (Sperr et al, 1992)
¥ CD49d (ITGA4, integrin-alpha-4, VLA-4, very late activation antigen 4, VLAA4, VLA4 receptor alpha 4 subunit, VLA-alpha 4, very late activation antigen alpha-4) (Kepley et al, 1998; Sperr et al, 1992; Warner et al, 1995; Quan et al, 2002; Schleimer et al, 1992)

¥ CD49e (fibronectin receptor alpha chain, FNRA, ITGA5, integrin-alpha-5, ECMR-6, Extracellular matrix receptor-6, class 6 ECMR, GPIc, platelet glycoprotein Ic, VLA-alpha 5, very late activation antigen alpha-5, VLA-5, very late activation antigen 5, VLA-5-alpha) (Sperr et al, 1992)
¥ CD50 (ICAM-3, intercellular adhesion molecule 3, ICAM-R, ICAM receptor) (FŸreder et al, 1994)
¥ CD54 (7F7, BB2, human rhinovirus receptor, ICAM-1, intercellular adhesion molecule 1, IFN-gamma regulated human melanoma-associated antigen, Ly47, MALA-2, Me14-D12, P3.58) (Yoshimura et al, 2002; Valent et al, 1990)
¥ CD55 (CD55a, CD55b, complement decay-accelerating factor, decay-accelerating factor, DAF, DAF-GPI, DAF-TM, GPI-DAF, TM-DAF, DAF1, decay-accelerating factor 1, DAF2, decay-accelerating factor 2, Cromer blood group antigen) (FŸreder et al, 1994, 1995, 2001)
¥ CD58 (LFA-3, lymphocyte function-associated antigen-3, T11TS, T11 target structure) (FŸreder et al, 1994)
¥ CD59 (CD59a, protectin, MIC11, MIN2, MIN3, MSK21, HRF20, homologous restriction factor-20 kDa, MACIF, membrane attack complex inhibitory factor, MAC-IP, MAC-inhibitory protein, H19, MIRL, membrane inhibitor of reactive lysis, P18, 1F5, 16.3A5, BRIC 229, YTH 53.1) (FŸreder et al, 1994, 1995, 2001)
¥ CD62L (gp90-MEL, LAM-1, leukocyte adhesion molecule 1, LECAM-1, leukocyte adhesion molecule 1, Leu8, LSEL, L-selectin, selectin-L, SELL, LYAM1, MEL-14, OX85, PLNHR, TQ-1) (Wimazal et al, 1999; Bochner and Sterbinsky, 1991)
¥ CD63 (81H, AD1, GP55, granulophysin, HOP-26, LIMP, lysosomal integral membrane protein, LIMP-1, lysosomal integral membrane protein-1, ME491, melanoma associated antigen ME491, MLA1, melanoma-associated antigen 1, NGA, neuroglandular antigen, NKI-C3, OMA81H, ocular melanoma-associated antigen 81H, PLTGP40, platelet glycoprotein gp40, TSPAN30, tetraspanin 30) (FŸreder et al, 1994; Siegmund et al, 2000; Sturm et al, 2004; Erdmann et al, 2003; Bellou et al, 2003; Hennersdorf et al, 2005; Kneidinger et al, 2008; Ono et al, 2010; Chirumbolo S et al, 2010; MacGlashan et al, 2010)
¥ CD65 (Ceramide dodecasaccharide, VIM-2) (Stain et al, 1987; Valent et al, 1990)
¥ CD68 (EBM11, gp110, Ki-M6, Ki-M7, KP-1, macrosialin, microsialin, PG-M1, PM-1k, SCARD1, scavenger receptor class D member 1, Y1/82A, Y2/131) (Pulford et al, 1990)
¥ CD69 (AIM, activation inducer molecule, BL-AC/P26, CLEC2C, C-type lectin domain family 2 member C, EA1, early antigen 1, early T-cell activation antigen p60, gp34/28, Leu23, MLR3, VEA) (Yoshimura-Uchiyama et al, 2003; Zhang et al, 2002; Ono et al, 2010)
¥ CD85a (CD85, LILRB3, leukocyte immunoglobulin-like receptor subfamily B member 3, ILT5, immunoglobulin-like transcript 5, LIR3, leukocyte immunoglobulin-like receptor 3, HL9, Monocyte inhibitory receptor HL9, PIRB, paired immunoglobulin-like receptor B) (Sloane et al, 2004)
¥ CD85h (LILRA2, leukocyte immunoglobulin-like receptor subfamily A member 2, ILT1, immunoglobulin-like transcript 1, LIR7, leukocyte immunoglobulin-like receptor 7) (MacGlashan et al, 2008; Sloane et al, 2004)
¥ CD88 (C5aR, C5a receptor, C5R1, complement component 5 receptor 1) (Eglite et al, 2000; FŸreder et al, 1994, 1995, 2001; Ghannadan et al, 2002; Wojta et al, 2002; Van Epps et al, 1993; Zahn et al, 1997; Zwirner et al, 1999; Ochsenberger et al, 1999, Heinemann et al, 2005)
¥ CD99 (12E7, MIC2, MIC2X, MIC2Y, E2 antigen, CD99R, O13, hec2, HBA-71) (FŸreder et al, 1994)
¥ CD107a (LAMP-1, lysosome-associated membrane glycoprotein-1, LAMPA, lysosome-associated membrane glycoprotein A, LGP120, lysosomal glycoprotein 120) (Hennersdorf et al, 2005)
¥ CD121b (FŸreder et al, 1994)
¥ CD122 (IL2 receptor-beta) (Siegmund et al, 2000)
¥ CD151 (PETA-3, platelet-endothelial cell tetraspan antigen 3, SFA-1, SF-HT activated gene 1, TSPAN24, tetraspanin 24, RAPH, Raph blood group) (Wimazal et al, 1999)
¥ CD157 (BST-1, bone marrow stromal cell antigen-1, Bsta1, 114/A10, ADP-ribosyl cyclase-2, BP-3, BP-3/IF-7, Cyclic ADP-ribose hydrolase 2, EC3.2.2.5, Ly65, MO-5) (Wimazal et al, 1999)
¥ CD162 (PSGL, P-selectin glycoprotein ligand, PSGL-1, P-selectin glycoprotein ligand-1, SELPLG [selectin-P ligand) (Taylor et al, 2000; Wimazal et al, 1999)
¥ CD164 (endolyn, endolyn-78, MGC-24, multiglycosylated core protein-24, MGC-24v, MUC-24) (Hennersdorf et al, 2005; Kneidinger et al, 2008)
¥ CD172A (BIT, brain Ig-like molecule with tyrosine-based activation motif, MFR, macrophage fusion receptor, MYD1, p84, PTPNS1, protein tyrosine phosphatase nonreceptor type substrate 1, OX41, SHPS1, SHP substrate 1, SIRP-alpha, SIRP-alpha-1, signal regulatory protein-alpha, tyrosine phosphatase SHP substrate 1) (Ghannadan et al, 2002)
¥ CD200R (CD200R1 CD200 receptor, CD200 receptor 1, OX2 receptor, OX2R, MOX2 receptor, MOX2R) (Kojima et al, 2007; Voehringer et al, 2004; Shiratori et al, 2004)
¥ CD203c (97A6 antigen, B10, bovine intestinal phosphodiesterase, ENPP-1, ectonucleotide pyrophosphatase/phosphatase 1, gp130RB13-6, Ly41, M6S1, membrane component chromosome 6 surface marker-1, NPP-3, nucleotide pyrophosphatase/phosphodiesterase 3, Pca-1, PD-1-beta, phosphodiesterase-1-beta, PDNP3, phosphodiesterase/nucleotide pyrophosphatase 3, tiptoe walking, ttw) (Ghannadan et al, 2002; Monneret et al, 2005; Buhring et al, 2004; FŸreder et al, 2001; Lourenco et al, 2008; Tokuda et al, 2009; Hennersdorf et al, 2005; Kneidinger et al, 2008; Potapinska et al, 2009; Chirumbolo S et al, 2010; Ono E et al, 2010; MacGlashan et al, 2010; Ciepiela et al, 2010)
¥ CD244 (2B4, 2B4-S, 2B4-L, C1.7, C9.1, Ly90, NAIL, NK-cell activation-inducing ligand, NKR2B4, natural killer cell receptor 2B4, NK-cell receptor 2B4, Nmrk, Non-MHC restricted killing associated, p38, SLAMF4, signaling lymphocyte activation molecule family member 4) (Romero et al, 2004; Nakajima et al, 1999)
¥ CD275 (B7-H2, B7RP-1, B7-related protein 1, GL50, H4, ICOSL, inducible T-cell co-stimulator ligand, ICOS ligand, KIAA0653, LICOS, ligand for ICOS) (Florian et al, 2006)
¥ CD302 (BIMLEC, CLEC13A, C-type lectin domain family 13 member A, DCL-1, DEC-205-associated C-type lectin-1) (Kato et al, 2007)
¥ CD305 (LAIR1, leukocyte-associated Ig-like receptor 1, 9.1C3) (Florian et al, 2006)
¥
CD312 (EMR2, EGF-like module containing mucin-like hormone receptor-like-2) (Florian et al, 2006)
¥ CDw17 (LacCer, lactosylceramide) (FŸreder et al, 1994; Ghannadan et al, 2002, Stain et al, 1987)
¥ common gamma (IL2RG, IL2 receptor-gamma, interleukin-2 receptor-gamma, gammac, gamma common, common cytokine receptor-gamma, cytokine receptor common subunit gamma, CD132, IMD4, immunodeficiency 4, SCIDX, X-linked severe combined immunodeficiency, SCIDX1, X-linked severe combined immunodeficiency-1, XSCID, X-linked severe combined immunodeficiency) (Siegmund et al, 2000)
¥¥ CXCL4 (CXC chemokine ligand 4, chemokine (C-X-C motif) ligand 4, PF4, platelet factor-4, Endothelial cell growth inhibitor, Heparin neutralizing protein, Megakaryocyte-stimulatory-factor, Oncostatin A, SCYB4) receptors (Brindley et al, 1983)
¥¥ CXCL7 (CXC chemokine ligand 7, chemokine (C-X-C motif) ligand 7, CTAP-3, Connective tissue activating protein-3, LA-PF4, low affinity platelet factor-4, LDGF, Leukocyte-derived growth factor, MDGF, macrophage-derived growth factor, NAP-2, Neutrophil-activating protein-2, PPBP, pro-platelet basic protein, PBP, platelet basic protein, SCYB7) receptors (Reddigari et al, 1992; Kuna et al, 1991, 1993)
¥ CXCL9 (CXC chemokine ligand 9, chemokine (C-X-C motif) ligand 9, mig, monokine induced by gamma-Interferon, Humig, Mumig, CRG-10, cytokine responsive gene-10, M119, SCYB9) (Pekarek V et al, 2007)
¥ CXCL10 (CXC chemokine ligand 10, chemokine (C-X-C motif) ligand 10, IP-10, INP-10, inflammatory protein 10, Interferon-inducible protein-10, IFN-inducible protein 10, immune protein-10; 10 kDa interferon-inducible protein, gamma-IP-10, CRG-2, cytokine responsive gene-2, C7, Ifi10, interferon-inducible-10, mob-1, SCYB10) (Pekarek V et al, 2007)
¥ CXCL11 (CXC chemokine ligand 11, chemokine (C-X-C motif) ligand 11, H174, beta-R1, I-TAC, Interferon-inducible T-cell alpha chemoattractant, IP-9, interferon-gamma-inducible protein-9, SCYB11, SCYB9B) (Pekarek V et al, 2007)
¥ CXCR4 (CXC-Chemokine receptor 4, LESTR, leukocyte-derived 7-transmembrane domain receptor, HUMSTR, NPYRL, neuropeptide Y receptor-like, NPY3R, neuropeptide Y receptor Y3, HM89, Fusin, LCR-1, FB22, LAP3, Lipopolysaccharide-associated protein 3, SDF-1 receptor, CD184, AURA86, augmented in rheumatoid arthritis 86) (Ghannadan et al, 2002; Iikura et al, 2001; Jinquan et al, 2000)
¥ Cystatin A (CSTA, Keratolinin, Stefin A, STFA, STF1, ACPI, acid cysteine proteinase inhibitor) (Mlinaric-Rascanet al, 1994)

¥ E-cadherin (epithelial cadherin, Arc-1, cadherin-1, CDH1, CAM 120/80, ECAD, L-CAM, liver cell adhesion molecule, Uvomorulin, rrl antigen, CD324) (Florian et al, 2006)

¥ Fc-epsilon R1 (Ghannadan et al, 2002; Pecaric-Petkovic et al, 2009)
¥¥ FPR1 (formyl peptide receptor-1, fMLP receptor, FRP, N-formyl peptide receptor, formyl peptide receptor) (de Paulis et al, 2004; Ochensberger et al, 1999)
¥¥ FPRL1 (formyl peptide receptor-like-1, FPRH1, formyl peptide receptor homolog-1, FPR2, formyl peptide receptor-2, lipoxin A4 receptor, ALXR, LXA4R, HM63) (de Paulis et al, 2004)
¥¥ FPRL2 (formyl peptide receptor-like-2, FPR-like-2, FPRH2, formyl peptide receptor homolog-2, FPR3, formyl peptide receptor-3) (de Paulis et al, 2004)

¥ glycophorin C (GYPC, CD236R, Ana blood group antigen, Duch blood group antigen, Gerbich blood group antigen, Lsa blood group antigen, Sialoglycoprotein D, Yus blood group antigen) (Ghannadan et al, 2002)
¥ GM-CSF (Granulocyte-macrophage colony stimulating factor, BPA, burst promoting activity, CSF-2, colony stimulating factor-2, GM-CSA, Granulocyte-macrophage colony stimulating activity, MGI-1GM, macrophage-granulocyte inducer, Pluripoietin-alpha) (Gilmartin et al, 2008; Kondo Y et al, 2008; Smithgall et al, 2008)
¥¥ GM-CSF (Granulocyte-macrophage colony stimulating factor, BPA, burst promoting activity, CSF-2, colony stimulating factor-2, GM-CSA, Granulocyte-macrophage colony stimulating activity, MGI-1GM, macrophage-granulocyte inducer, Pluripoietin-alpha) receptors (CSF2RA, CSF-2 receptor-A, Colony stimulating factor-2 receptor A, Colony stimulating factor-2 receptor-alpha, CSF2R, CSF-2 receptor, Colony stimulating factor-2 receptor, CSF2RY, GMCSFR, GM-CSF receptor, CDw116, CD116; common beta, beta c, betac, common cytokine receptor-beta, cytokine receptor common subunit beta, IL3RB, IL3 receptor subunit beta, IL3R-beta, IL5RB, IL5 receptor subunit beta, IL5R-beta, GM-CSF receptor subunit beta, CSF2RB, colony stimulating factor-2 receptor-beta, CD131) (Hirai et al, 1992; Quan et al, 2002; Tedeschi et al, 1999; Tsuda et al, 1991; Yamaguchi et al, 1992; Yoshimura-Uchiyama et al, 2003; Siegmund et al, 2000; Toba et al, 1999)
¥¥ gp130 (IL6ST, IL6 signal transducer, IL6R-beta, IL6RB, CDw130, CD130) (Siegmund et al, 2000)
¥ GPR44 (G-protein-coupled receptor-44, CRTH2, chemoattractant receptor-homologous molecule expressed on Th2 cells, DL1R, CD294) (Nagata et al, 1999; Yoshimura-Uchiyama et al, 2004)
¥ Granzyme B (GZMB, Granzyme 2, serine protease B, SE-2, serine esterase-2, CSP-B, cytotoxic serine protease B, CCP1, cytotoxic cell protease-1, Asp-ase, CGL1, cathepsin G-like-1, CTLA-1, cytotoxic T-lymphocyte-associated serine esterase-1, fragmentin-2, RNKP1, rat natural killer protease-1) (Tschopp et al, 2006)

¥ HGF (hepatocyte growth factor, HGF/SF, Hepatocyte growth factor-scatter factor, F-TCF, fibroblast tumor cytotoxic factor, HPTA, Hepatopoietin A, SF, scatter factor, TCF, tumor cytotoxic factor, Lung fibroblast-derived mitogen) (Cerny-Reiterer et al, 2012)

¥ ICAM-2 (intercellular adhesion molecule 2, Ly60, CD102) (FŸreder et al, 1994)
¥¥ IFN-alpha (interferon-alpha, Alpha-Interferon, aIFN, B-cell interferon, Leukocyte interferon, LeIFN, Lymphoblast interferon, LyIFN-alpha) receptors (IFNAR1, IFN-alpha/beta receptor 1, interferon (alpha, beta and omega) receptor 1, IFN-alphaR1, IFRC, IFNAR, IFNAR2, IFN-alpha/beta receptor 2, interferon (alpha, beta and omega) receptor 2, IFN-alphaR2, IFNABR) (Chen et al, 2003)
¥ IFN-beta (Beta-Interferon, Interferon-beta, bIFN, Fibroblast interferon, Fi-IFN, F-IFN) receptors (Chen et al, 2003)
¥ IGF-1 (Insulin-like growth factor-1, Erythropoietic factor, mechano growth factor, MGF, ILGF1, somatomedin C, NSILA, non-suppressible insulin-like activity, Somatomedin A, Somatomedin C, sulfation factor, Mecasermin) receptors (IGF1R, CD221, JTK13) (Hirai et al, 1993; Hartnell et al, 2004)
¥¥ IGF-2 (Insulin-like growth factor-2, Growth-promoting activity for vascular endothelial cells, T3M-11-derived growth factor, ILGF2, MSA, multiplication stimulating activity, NSILA, non-suppressible insulin-like activity, Somatomedin A, sulfation factor, SGF, skeletal growth factor, HP1-SMP, HP3-SMP, Somatomedin/insulin-like growth factor-like polypeptides, C11orf43, chromosome 11 open reading frame 43) receptors (IGF2R, CD222, mannose-6-phosphate receptor; MPR, CIM6PR, cation-independent mannose 6-phosphate receptor, MPRI, MPR300) (Hartnell et al, 2004)
¥¥ IL1 (interleukin-1) receptors (IL1RA, IL1R-alpha, IL1 receptor-alpha; interleukin-1 receptor-alpha, IL1R1, IL1 receptor type 1, Interleukin-1 receptor 1, IL1 receptor R1, CD121a; IL1RB, IL1R-beta, IL1 receptor-beta; interleukin-1 receptor-beta, IL1R2, IL1 receptor type 2, Interleukin-1 receptor 2, IL1 receptor R2, CD121b, AURA31, augmented in rheumatoid arthritis 31) (Haak-Frendscho et al, 1988; Agis et al, 1996)
¥ IL1-beta (IL1B, interleukin-1-beta, IL1F2, Interleukin-1 family member 2, Catabolin, H1, Hematopoietin-1, IFN-beta inducing factor, Interleukin-beta, OAF, osteoclast activating factor) (King et al, 2000; Smithgall et al, 2008)
¥¥ IL2 (Interleukin-2, BF, blastogenic factor, EDF, eosinophil differentiation factor, KHF, killer cell helper factor, LMF, lymphocyte mitogenic factor, LPF, lymphocyte proliferation factor, MAF-C I, macrophage-activating factor for cytotoxicity I, PFC-EA, plaque forming cell enhancing factor, SCIF, secondary cytotoxic T-cell inducing factor, TCGF, T-cell growth factor, TCPA, T colony-promoting activity, TDF, thymocyte differentiation factor, T-LPF, T-lymphocyte promotor factor, TMF, thymocyte mitogenic factor, T-cell maturation factor, T-cell mitogenic factor, TRF-3, T-cell replacing factor-3, TSF, thymocyte stimulating factor) receptors (IL2RA, interleukin-2 receptor-alpha; IL2R-alpha; IL2 receptor-alpha, IL2R, interleukin-2 receptor, TAC antigen, TCGFR, T-cell growth factor receptor, IDDM10, insulin-dependent diabetes mellitus 10, CD25; Ly43, lymphocyte antigen 43, OX39, IL2RB, interleukin-2 receptor-beta; IL2R-beta; IL2 receptor-beta, CD122; IL2RG, IL2 receptor-gamma, interleukin-2 receptor-gamma, IL2R-gamma, common gamma, gammac, gamma common, common cytokine receptor-gamma; cytokine receptor common subunit gamma, CD132, SCIDX1, X-linked severe combined immunodeficiency-1) (Agis et al, 1996; FŸreder et al, 1994; Toba et al, 1999; Takahashi et al, 1993; Stain et al, 1987; Maggiano et al, 1990; Tsuda et al, 1991; Han et al, 2008)
¥¥ IL3 (Interleukin-3, 20-alpha-hydroxysteroid dehydrogenase inducing factor, BPA, burst promoting activity, CFU-S, colony-forming unit spleen, CSF-2-alpha, colony stimulating factor-2-alpha, CSF-2-beta, colony stimulating factor-2-beta, ECSF, erythroid colony stimulating factor, Eo-CSF, eosinophil colony stimulating factor, HCGF, Hematopoietic cell growth factor, HP2, Hematopoietin-2, HPGF, hematopoietic cell growth factor, MCGF, mast cell growth factor, MCSA, multi-colony stimulating activity, Meg-CSF, megakaryocyte colony stimulating factor, MGF, mast cell growth factor, Mixed colony stimulating factor, Multi-CSF, Multi-colony stimulating factor, multi-HGF, multilineage hemopoietic growth factor, Multipoietin, NC cell growth factor, natural cytotoxic cell growth factor, Neutrophil-granulocyte colony stimulating factor, PSF, progenitor stimulating factor, PSH, panspecific hemopoietin, SAF, stem cell activating factor, Thy1 inducing factor) receptors (IL3RA, interleukin-3 receptor-alpha, IL3R-alpha, common beta, beta c, betac, common cytokine receptor-beta, cytokine receptor common subunit beta, IL3RB, IL3 receptor subunit beta, IL3R-beta, IL3 receptor subunit beta; interleukin-3 receptor-beta, IL5RB, IL5 receptor subunit beta, IL5R-beta, GM-CSF receptor subunit beta, CSF2RB, colony stimulating factor-2 receptor-beta, CD131) (Agis et al, 1996; Yoshimura-Uchiyama et al, 2003; Yoshimura et al, 2002; FŸreder et al, 2001; Hirai et al, 1992; Lopez et al, 1990; Miura et al, 2001; Quan et al, 2002; Schneider et al, 1999; Lourenco et al, 2008; Spiegl et al, 2008; Toba et al, 1999; Didichenko et al, 2008; Tschopp et al, 2006; Han et al, 2008; Kondo Y et al, 2008; Suzukawa M et al, 2008; Chirumbolo S et al, 2010)
¥ IL4 (Interleukin-4, BCDF-epsilon, B-cell differentiation factor-epsilon, BCDF-gamma, B-cell differentiation factor-gamma, BCGF-gamma, B-cell growth factor-gamma, BCGF-1, B-cell growth factor-1, Binetrakin, BSF-1, B-cell stimulating factor-1, BSF-p1, B-cell stimulating factor p1, EL4-BCGF, EL4 B-cell growth factor, HCGF, Hodgkin's cell growth factor, IgE-EF, IgE enhancing factor, IgG1-enhancing factor, IgG1-induction factor, LMW-BCGF, low molecular weight B-cell growth factor, MaGEF, Mast cell growth enhancing factor, MCGF-2, mast cell growth factor-2, MFF, macrophage fusion factor, Pitrakinra, TCGF-2, T-cell growth factor-2) (Gibbs et al, 1996; Higa et al, 2003; Kasaian et al, 1996; Khodoun et al, 2004; Min et al, 2004; Hirano et al, 2004; Brunner et al, 1993; Arock et al, 1993; Devouassoux et al, 2002; Yanagihara et al, 1998; Schneider et al, 1999; Gessner et al, 2005; Kondo Y et al, 2008; Pecaric-Petkovic T et al, 2009; Smithgall et al, 2008; Suzukawa M et al, 2008)
¥¥ IL4 (Interleukin-4, BCDF-epsilon, B-cell differentiation factor-epsilon, BCDF-gamma, B-cell differentiation factor-gamma, BCGF-gamma, B-cell growth factor-gamma, BCGF-1, B-cell growth factor-1, Binetrakin, BSF-1, B-cell stimulating factor-1, BSF-p1, B-cell stimulating factor p1, EL4-BCGF, EL4 B-cell growth factor, HCGF, Hodgkin's cell growth factor, IgE-EF, IgE enhancing factor, IgG1-enhancing factor, IgG1-induction factor, LMW-BCGF, low molecular weight B-cell growth factor, MaGEF, Mast cell growth enhancing factor, MCGF-2, mast cell growth factor-2, MFF, macrophage fusion factor, Pitrakinra, TCGF-2, T-cell growth factor-2) receptors (IL4RA, IL4R-alpha, interleukin-4 receptor-alpha, IL4R, interleukin-4 receptor, CD124) (Siegmund et al, 2000)
¥ IL5 (Interleukin-5, B151-TRF, B151 T-cell replacing factor, BCDF, B-cell differentiation factors, BCDF-alpha, B-cell differentiation factor-alpha, BCDF-mu, B-cell differentiation factor-mu, BCGF-2, B-cell growth factor-2, DL-BCGF, Dennert line B-cell growth factor, BGDF, B-cell growth and differentiation factor, CFU-Eo GSF, colony-forming unit eosinophil growth stimulating factor, EDF, eosinophil differentiation factor, Eo-CSF, Eosinophil colony stimulating factor, Eo-DF, eosinophil differentiation factor, ESP, eosinophil stimulation promoter, IgA-EF, IgA enhancing factor, KHF, killer helper factor, TRF-1, T-cell replacing factor-1) (Higa et al, 2003; Smithgall et al, 2008)
¥¥ IL5 (Interleukin-5, B151-TRF, B151 T-cell replacing factor, BCDF, B-cell differentiation factors, BCDF-alpha, B-cell differentiation factor-alpha, BCDF-mu, B-cell differentiation factor-mu, BCGF-2, B-cell growth factor-2, DL-BCGF, Dennert line B-cell growth factor, BGDF, B-cell growth and differentiation factor, CFU-Eo GSF, colony-forming unit eosinophil growth stimulating factor, EDF, eosinophil differentiation factor, Eo-CSF, Eosinophil colony stimulating factor, Eo-DF, eosinophil differentiation factor, ESP, eosinophil stimulation promoter, IgA-EF, IgA enhancing factor, KHF, killer helper factor, TRF-1, T-cell replacing factor-1) receptors (IL5RA, IL5R-alpha, interleukin-5 receptor, interleukin-5 receptor-alpha, IL5RB, IL5R-beta, interleukin-5 receptor-beta, CD125, CDw125, common beta, beta c, betac, common cytokine receptor-beta, cytokine receptor common subunit beta, IL3RB, IL3 receptor subunit beta, IL3R-beta, IL5RB, IL5 receptor subunit beta, IL5R-beta, GM-CSF receptor subunit beta, CSF2RB, colony stimulating factor-2 receptor-beta, CD131) (Denburg et al, 1991; Yoshimura-Uchiyama et al, 2003; Hirai et al, 1990; Hirai et al, 1992; Lopez et al, 1990; Miura et al, 2001; Quan et al, 2002; Toba et al, 1999)
¥ IL6 (interleukin-6, 26 kDa protein, BSF-2, B-cell stimulating factor-2, CDF, CAT development factor, choline acetyltransferase development factor, Cytolytic differentiation factor for T-lymphocytes, FDGI, fibroblast-derived growth inhibitor, hybridoma growth factor, HPGF, hybridoma/plasmacytoma growth factor, HSF, hepatocyte stimulating factor, HSF-1, hepatocyte stimulating factor-1, ILHP1, Interleukin-hemopoietin-1, MGI-2A, Macrophage-granulocyte inducer-2A, Myeloma GF, myeloma growth factor, NKAF, natural killer cell activating factor, TAF, T-cell activating factor, Thymocyte growth factor, TSF, thymocyte stimulating factor) (Higa et al, 2003; King et al, 2000; KrŸger-Krasagakes et al, 1996; Schneider et al, 1999; Kondo Y et al, 2008; Smithgall et al, 2008)
¥¥ IL6 (interleukin-6, 26 kDa protein, BSF-2, B-cell stimulating factor-2, CDF, CAT development factor, choline acetyltransferase development factor, Cytolytic differentiation factor for T-lymphocytes, FDGI, fibroblast-derived growth inhibitor, hybridoma growth factor, HPGF, hybridoma/plasmacytoma growth factor, HSF, hepatocyte stimulating factor, HSF-1, hepatocyte stimulating factor-1, ILHP1, Interleukin-hemopoietin-1, MGI-2A, Macrophage-granulocyte inducer-2A, Myeloma GF, myeloma growth factor, NKAF, natural killer cell activating factor, TAF, T-cell activating factor, Thymocyte growth factor, TSF, thymocyte stimulating factor) receptors (IL6RA, IL6R-alpha, IL6R, interleukin-6 receptor, interleukin-6 receptor-alpha, CD126, IL6ST, IL6 signal transducer, interleukin-6 signal transducer, IL6R-beta, interleukin-6 receptor-beta, IL6RB, CDw130, CD130) (Toba et al, 1999)
¥ IL8 (interleukin-8, SCYB8, 3-10C, 9E3, ANAP, anionic neutrophil-activating peptide, Chemotaxin, CEF-4, CT/IL8, CXCL8, CXC chemokine ligand 8, chemokine (C-X-C motif) ligand 8, EDNAP, endothelial-derived neutrophil-activating peptide, EMF-1, embryo fibroblast protein 1, Emoctakin, ENAP, Endothelial cell neutrophil-activating peptide, FDNAP, Fibroblast-derived neutrophil-activating peptide, FINAP, fibroblast-derived neutrophil-activating protein, GCF, granulocyte chemotactic factor, GCP, granulocyte chemotactic peptide, LAI, leukocyte adhesion inhibitor, LCF, lymphocyte chemotactic factors, LDNAP, leukocyte-derived neutrophil-activating peptide, leukocyte inhibitory factor, LUCT, lung carcinoma-derived chemotaxin, LYNAP, lymphocyte-derived neutrophil-activating peptide, MDNAP, monocyte-derived neutrophil-activating peptide, MDNCF, monocyte-derived neutrophil chemotactic factor, MOC, monocyte-derived chemotaxin, MONAP, monocyte-derived neutrophil-activating peptide, NAF, neutrophil-activating factor, NAP-1, neutrophil-activating protein-1, NCF, neutrophil chemotactic factor, NCP, neutrophil chemotactic protein, PLF, psoriatic leukotactic factor, TCF, T-cell chemotactic factor, TSG-1, Tumor necrosis factor-stimulated gene sequence-1) (Higa et al, 2003; Markvardsen et al, 1995; Gilmartin et al, 2008; Pecaric-Petkovic et al, 2009; Smithgall et al, 2008)
¥¥ IL8 (interleukin-8, SCYB8, 3-10C, 9E3, ANAP, anionic neutrophil-activating peptide, Chemotaxin, CEF-4, CT/IL8, CXCL8, CXC chemokine ligand 8, chemokine (C-X-C motif) ligand 8, EDNAP, endothelial-derived neutrophil-activating peptide, EMF-1, embryo fibroblast protein 1, Emoctakin, ENAP, Endothelial cell neutrophil-activating peptide, FDNAP, Fibroblast-derived neutrophil-activating peptide, FINAP, fibroblast-derived neutrophil-activating protein, GCF, granulocyte chemotactic factor, GCP, granulocyte chemotactic peptide, LAI, leukocyte adhesion inhibitor, LCF, lymphocyte chemotactic factors, LDNAP, leukocyte-derived neutrophil-activating peptide, leukocyte inhibitory factor, LUCT, lung carcinoma-derived chemotaxin, LYNAP, lymphocyte-derived neutrophil-activating peptide, MDNAP, monocyte-derived neutrophil-activating peptide, MDNCF, monocyte-derived neutrophil chemotactic factor, MOC, monocyte-derived chemotaxin, MONAP, monocyte-derived neutrophil-activating peptide, NAF, neutrophil-activating factor, NAP-1, neutrophil-activating protein-1, NCF, neutrophil chemotactic factor, NCP, neutrophil chemotactic protein, PLF, psoriatic leukotactic factor, TCF, T-cell chemotactic factor, TSG-1, Tumor necrosis factor-stimulated gene sequence-1) receptors (IL8RA, IL8R-alpha, interleukin-8 receptor-alpha; interleukin-8 receptor type A, IL8R1, IL8 receptor-1, interleukin-8 receptor type 1, CMKAR1, chemokine-alpha receptor 1, CXCR1, CD181, IL8RB, IL8R-beta, interleukin-8 receptor-beta; interleukin-8 receptor type B, IL8R2, IL8 receptor-2, interleukin-8 receptor type 2, CMKAR2, chemokine-alpha receptor 2, CXCR2, CD182) (Alam et al, 1992; Kuna et al, 1991; Iikura et al, 2001; Ochensberger et al, 1999; Florian et al, 2006)
¥ integrin-beta-7 (Bochner et al, 1996; Wimazal et al, 1999)
¥ IL13 (Interleukin-13, NC30, P600) (Higa et al, 2003; Hirano et al, 2004; Li et al, 1996; Ochsenberger et al, 1996; Gibbs et al, 1996; Yanagihara et al, 1998; Sin et al, 2001; Li et al, 1996; Gessner et al, 2005; Gilmartin et al, 2008; Pecaric-Petkovic et al, 2009; Tschopp et al, 2006; Kondo Y et al, 2008; Smithgall et al, 2008; Suzukawa M et al, 2008)
¥¥ IL16 (Interleukin-16, Lymphocyte chemoattractant factor, LCF) receptors (Qi et al, 2002)
¥¥ IL17 (Interleukin-17, IL17A, interleukin-17A) receptors (IL17RA, interleukin-17 receptor A, IL17 receptor A, CD217, CDw217) (Willheim et al, 1995)
¥¥ IL18 (interleukin-18, IGIF, IFN-gamma inducing factor, IL1-gamma, IL1F4, IL1 family member 4, Iboctadekin) receptors (IL18R1, interleukin-18 receptor-1, IL18R-alpha, IL18RA, interleukin-18 receptor-alpha, IL1Rrp, IL1 receptor-related protein, IL1R5, IL1 receptor R5, Interleukin-1 receptor 5, CD218a, CDw218a) (Yoshimoto et al, 1999; Kondo Y et al, 2008; Florian et al, 2006)
¥ IL25 (interleukin-25, IL17E, interleukin-17E) (Wang YH et al, 2007)
¥¥ IL29 (IFN-lambda-1, interferon-lambda-1, IFNL1) receptors (IL28RA, interleukin-28 receptor-alpha, IL28R-alpha, IL28R1, interleukin-28 receptor-1, IFN-lambda-R1, IFN-lambda receptor 1; interferon-lambda receptor-1, IFNLR1, IFNLR, interferon-lambda receptor, CRF2-12, Cytokine receptor family 2 member 12, LICR2, Likely Interleukin or Cytokine Receptor-2) (Pekarek et al, 2007)
¥¥ IL31 (interleukin-31) receptors (IL31RA, interleukin-31 receptor A; IL31 receptor-alpha; IL31R-alpha, GLMR, gp130-like monocyte receptor, GPL, gp130-like receptor, CRL3, cytokine receptor-like 3; OSMR, oncostatin M receptor, OSMRB, Oncostatin-M receptor-beta; OSMR-beta; Oncostatin-M-specific receptor subunit beta, IL31R-beta, IL31RB, IL31 receptor-beta, Interleukin-31 receptor-beta) ( Diveu et al, 2003)
¥¥ IL33 (interleukin-33, NFHEV, nuclear factor from high endothelial venules, C9orf26, chromosome 9 open reading frame 26, DVS27) receptors (IL33R, IL1RL1, IL1 receptor-like-1, IL1R4, IL1 receptor R4, interleukin-1 receptor 4, T1, T1/ST2, ST2, ST2L, Fit-1, fos-induced transcript-1, Ly84, lymphocyte antigen 84, DER4, delayed early response gene 4) (Kondo Y et al, 2008; Pecaric-Petkovic T et al, 2009; Schneider et al, 2009; Suzukawa M et al, 2008; Smithgall et al, 2008; Silver et al, 2010)
¥ insulysin (insulin-degrading enzyme, IDE, insulin protease, insulin proteinase, insulinase, EC3.4.24.56, AURA99, augmented in rheumatoid arthritis 99) (Weirich et al, 2008)

¥ JAM1 (Junctional adhesion molecule 1, JAM-A, Junctional adhesion molecule A, JCAM, Platelet F11 receptor, F11R, F11 receptor, platelet adhesion molecule 1, PAM-1, Ly106, lymphocyte antigen 106, CD321) (Florian et al, 2006)
¥ JAM2 (Junctional adhesion molecule 2, VEJAM, vascular endothelial junctional adhesion molecule, JAM-B, Junctional adhesion molecule B) (Florian et al, 2006)

¥ leptin (ob, ob/ob, obese protein, obesity factor, Metreleptin) (Gilmartin et al, 2008)

¥ MAFA (Mast-cell-function-associated antigen, MAFA-L, MAFA-like, CLEC15A, C-type lectin domain family 15 member A, KLRG1, killer cell lectin-like receptor G1) (Butcher et al, 1998)
¥ Mcl-1 (myeloid cell factor-1, myeloid cell leukemia sequence 1, BCL2L3) (Didichenko et al, 2008)
¥ MMCP-8 mouse mast cell serine protease 8 (Poorafshar et al, 2000)

¥ NAP-1 receptors (White et al, 1989; Dahinden et al, 1989)
¥ NAP-2 receptors (Reddigari et al, 1992; Kuna et al, 1993)
¥ neuropilin-1 (Neuropilin, NPN-1, NP-1, NRP1, A5-antigen, BDCA4, Blood dendritic cell antigen 4, VEGF-165R, CD304) (de Paulis et al, 2006)
¥ neuropilin-2 (NPN-2, NP-2, NRP2) (de Paulis et al, 2006)
¥¥ NGF (nerve growth factor, 7S NGF, 7S nerve growth factor, NGF-alpha, Nerve growth factor-alpha, kallikrein Klk1b4, Klk1b4, NGF-beta, NGFB, Nerve growth factor-beta, NGFG, NGF-gamma, Nerve growth factor-gamma, kallikrein Klk1b3, Klk1b3) receptors (NGFR, p75NTR, p75 neurotrophin receptor, p75LNGFR, p75NGFR, LNGFR, p75 low affinity NGF receptor, TNFRSF16, TNF receptor superfamily member 16, CD271) (Bischoff and Dahinden, 1992; Sin et al, 2001; Miura et al, 2001; Tsuda et al, 1991)
¥¥ nociceptin (PNOC, PPNOC, Orphanin FQ, Nociceptin/Orphanin FQ, N/OFQ, Orphanin FQ/Nociceptin, OFQ/N) receptors (LC132, NOCIR, OPRL1, ORL1, opioid receptor-like 1, opiate receptor-like 1, OP4, opioid receptor 4, NOP, non-classical opioid receptor) (KrŸger et al, 2006)

¥ PAI-1 (Plasminogen activator inhibitor-1, PAI, plasminogen activator inhibitor, endothelial plasminogen activator inhibitor, Serpin E1, MSF, monocyte suppressor factor, EIP-1, EGF-inducible protein 1, mesosecrin) (Wojta et al, 2002)
¥ PDGF (platelet-derived growth factor, PDGF-1, PDGF-2, PDGF-A, PDGF-AA, PDGF-B, PDGF-BB, FDGF, fibroblast-derived growth factor, GDGF, glioma-derived growth factor-1, GDGF-2, glioma-derived growth factor-2, GSM, Glucocorticoid-suppressible mitogenic activity, MDF, mesangial cell proliferating factor, MDGF, monocyte-derived growth factor, OBIF, osteoblastogenesis inhibitory factor, ODGF, osteosarcoma-derived growth factor, T47D factor) (Forsberg et al, 1993)
¥ platelet-activating factor receptors (Ochensberger et al, 1999)

¥ Relaxin (RLN, RLX, RLN1, relaxin 1, relaxin H1, H1 relaxin, RLXH1, RXN1, RLN2, relaxin 2, relaxin H2, H2 relaxin, RLXH2, RXN2, relaxin 1/2) (Bani et al, 2002)
¥ RIG-I (Retinoic acid inducible gene-I, DDX58, DEAD box polypeptide 58, DEAD/H BOX 58) (Zhang NN et al, 2008)

¥¥ SCF (stem cell factor, HLGF-1, hemolymphopoietic growth factor-1), kit ligand, KITL, KITLG, Mast/stem cell growth factor, MGF, mast cell growth factor, SLF, steel factor) receptors (kit, SCFR, CD117) (Heinemann et al, 2005; Koketsu R et al, 2008)
¥ serglycin (SRGN, PRG1, PRG, PPG, platelet proteoglycan protein core) (Stellrecht et al, 1991; Toyama-Sorimachi et al, 1997)
¥ SIGLEC-5 (sialic acid binding immunoglobulin-like lectin 5, SIGLEC-F, CD33L2, CD33-like-2, OBBP2, Ob binding protein 2, CD170) (Ghannadan et al, 2002)
¥ SIGLEC-8 (sialic acid binding immunoglobulin-like lectin 8, SAF-2, sialoadhesin family member 2) (Kikly et al, 2000)
¥¥ somatostatin (SST, Somatotropin release inhibiting hormone, SIH, Somatotropin release inhibiting factor, SRIF, growth hormone-inhibiting hormone, GIH, growth hormone release inhibitory hormone, GH-RIH) receptors (Goetzl et al, 1985; Goetzl and Payan, 1988)
¥¥ substance P (Neurokinin-1, NK1, NKA, Neurokinin A, Tac1, tachykinin-1) receptors (Louis and Radermecker, 1990)

¥ TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor, TNFRSF13B, TNF receptor superfamily member 13B, CD267) (Florian et al, 2006)
¥¥
TCTP (translationally controlled tumor protein, TPT1, tumor protein translationally-controlled-1, fortilin, p23, IgE-HRF, IgE-dependent histamine releasing factor) receptors (Nielsen et al, 1998; Vonakis et al, 2008)
¥ thymosin-beta-4 (TMSB4, TMSB4X, Tb4, Tbeta-4, 6-26, Fx, PTMB4, THYB4) (Cassimeris et al, 1992)
¥ TLR-4 (Toll-like receptor-4, human Toll, TOLL, Ly87, Rasl2-8, CD284) (FLorian et al, 2006)
¥¥ TRAIL (TNF-related apoptosis inducing ligand, APO-2 ligand, APO-2L, TL2, TNF-like-2, TNF ligand superfamily member 10, TNFSF10, Ly81, CD253) receptor-1 (TRAIL receptor-1, TRAIL-R1, TRAIL-R, TRAIL receptor, DR4, death receptor-4, APO-2, TNFRSF10A, TNF receptor superfamily member 10A, CD261) (Florian et al, 2006)
¥¥ TRAIL (TNF-related apoptosis inducing ligand, APO-2 ligand, APO-2L, TL2, TNF-like-2, TNF ligand superfamily member 10, TNFSF10, Ly81, CD253) receptor-2 (TRAIL receptor-2, TRAIL-R2, death receptor-5, DR5, KILLER, TRICK2, TRAIL receptor inducer of cell killing-2, TNFRSF10B, TNF receptor superfamily member 10B, CD262, Ly98) (Florian et al, 2006)
¥¥ transferrin (TRF, DF-77, GPBP, granulocyte/pollen-binding protein, Lung-derived growth factor) receptors (CD71, TFR, TFR1, TRFR, TFRC, OKT9, T9, OX26) (Toba et al, 1999)

¥ VASP (Vasodilator-stimulated phosphoprotein) (HalbrŸgge et al, 1992; Reinhard et al, 1992)
¥ VEGF-121 (VEGF-A121, VEGF, vascular endothelial growth factor, VEGF-A, vascular endothelial growth factor A, VEGF-1, vascular endothelial growth factor-1, VEG/PF, vascular endothelial growth factor/vascular permeability factor, GD-VEGF, glioma-derived vascular endothelial growth factor, VAS, Vasculotropin, Vascular endothelial cell proliferation factor, VPF, vascular permeability factor, FSdGF, Folliculo stellate cell-derived growth factor) (de Paulis et al, 2006)
¥ VEGF-165 (VEGF-A165, VEGF, vascular endothelial growth factor, VEGF-A, vascular endothelial growth factor A, VEGF-1, vascular endothelial growth factor-1, VEG/PF, vascular endothelial growth factor/vascular permeability factor, GD-VEGF, glioma-derived vascular endothelial growth factor, VAS, Vasculotropin, Vascular endothelial cell proliferation factor, VPF, vascular permeability factor, FSdGF, Folliculo stellate cell-derived growth factor) (de Paulis et al, 2006)
¥ VEGF-189 (VEGF-A189, VEGF, vascular endothelial growth factor, VEGF-A, vascular endothelial growth factor A, VEGF-1, vascular endothelial growth factor-1, VEG/PF, vascular endothelial growth factor/vascular permeability factor, GD-VEGF, glioma-derived vascular endothelial growth factor, VAS, Vasculotropin, Vascular endothelial cell proliferation factor, VPF, vascular permeability factor, FSdGF, Folliculo stellate cell-derived growth factor) (de Paulis et al, 2006)
¥ VEGF-B (vascular endothelial growth factor B, VEGF-B(167), VEGF-B(186), VRF, VEGF related factor, VRP, VEGF related protein) (de Paulis et al, 2006)
¥¥ VEGF-A (Vascular endothelial growth factor A; VEGF-1, vascular endothelial growth factor-1, VEGF, vascular endothelial growth factor; vasculo-endothelial growth factor, VEG/PF, vascular endothelial growth factor/vascular permeability factor, GD-VEGF, glioma-derived vascular endothelial growth factor, VAS, Vasculotropin, Vascular endothelial cell proliferation factor; VPF, vascular permeability factor, Mouse sarcoma 180-derived growth factor; FSdGF, Folliculo stellate cell-derived growth factor) receptors (de Paulis et al, 2006)

Copyright © 2012 by H IBELGAUFTS. All rights reserved.
ENTRY LAST MODIFIED: February 2010



 

See REFERENCES for entry basophils.

Click BACKLINKS to see which COPE entries contain the term basophils .




COPE Homepage Top of Page


 
 
SUPPORT COPE | Santa Claus | Intro | Subdictionaries | New Entries | Contribute data | COPE Credentials
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Please inquire. COPE is looking for long-term support from a company appreciating and committed to communication biology

              Created, developed, and maintained by Prof Dr H Ibelgaufts              
About the author of COPE
  |    Contact COPE   |    postcard and stampware   |    Terms & Conditions


Access to COPE is free only for academic institutions and non-profit organizations.
OTHER USERS: must contact COPE and pay a site licence fee.

U L T R A   P O S S E   N E M O   O B L I G A T U R